Recurrence risk in symptomatic intracranial stenosis treated medically in the real world
Yaghi S, Shu L, Goldstein E, Chang A, Kala N, Stretz C, Burton T, Perelstein E, Furie K, Jayaraman M, Torabi R, Moldovan K, de Havenon A, Khatri P, Gebregziabher M, Liebeskind D, Prabhakaran S. Recurrence risk in symptomatic intracranial stenosis treated medically in the real world. Journal Of Stroke And Cerebrovascular Diseases 2023, 32: 107086. PMID: 37030126, DOI: 10.1016/j.jstrokecerebrovasdis.2023.107086.Peer-Reviewed Original ResearchConceptsIntracranial atherosclerotic stenosisSymptomatic intracranial atherosclerotic stenosisClinical trialsRecurrence riskRecurrent strokeInclusion criteriaReal-world settingMaximal medical treatmentRecurrent stroke rateDual antiplatelet therapyAcute ischemic strokeReal-world cohortSymptomatic intracranial stenosisPharmacological treatment strategiesCox regression modelMeeting inclusion criteriaLow event ratesAntiplatelet therapyStroke RegistryIschemic eventsIschemic strokeWorld CohortHospitalized patientsEarly recurrenceIntracranial stenosis